Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapy

This review has been withdrawn.

The reason for withdrawal and previous versions are archived and accessible within the withdrawn record in the Cochrane Library.

Health topics:

Published:

12 September 2019

Authors:

Katz LH, Fraser A, Leibovici L, Tur-Kaspa R, Goldvaser H

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Katz LH, Fraser A, Leibovici L, Tur-Kaspa R, Goldvaser H. Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapy. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No.: CD005264. DOI: 10.1002/14651858.CD005264.pub3